UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

Olesen, J.; Diener, H.-C.; Husstedt, I.G.; Goadsby, P.J.; Hall, D.; Meier, U.; Pollentier, S.; (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine , 350 (11) pp. 1104-1110. 10.1056/NEJMoa030505. Green open access

[thumbnail of 9380.pdf]
Preview
PDF
9380.pdf

Download (100kB)

Abstract

Background: Calcitonin gene–related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks. Methods: In an international, multicenter, double-blind, randomized clinical trial of BIBN 4096 BS, a highly specific and potent nonpeptide CGRP-receptor antagonist, 126 patients with migraine received one of the following: placebo or 0.25, 0.5, 1, 2.5, 5, or 10 mg of BIBN 4096 BS intravenously over a period of 10 minutes. A group-sequential adaptive treatment-assignment design was used to minimize the number of patients exposed. Results: The 2.5-mg dose was selected, with a response rate of 66 percent, as compared with 27 percent for placebo (P=0.001). The BIBN 4096 BS group as a whole had a response rate of 60 percent. Significant superiority over placebo was also observed with respect to most secondary end points: the pain-free rate at 2 hours; the rate of sustained response over a period of 24 hours; the rate of recurrence of headache; improvement in nausea, photophobia, phonophobia, and functional capacity; and the time to meaningful relief. An effect was apparent after 30 minutes and increased over the next few hours. The overall rate of adverse events was 25 percent after the 2.5-mg dose of the drug and 20 percent for the BIBN 4096 BS group as a whole, as compared with 12 percent for placebo. The most frequent side effect was paresthesia. There were no serious adverse events. Conclusions: The CGRP antagonist BIBN 4096 BS was effective in treating acute attacks of migraine.

Type: Article
Title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
Open access status: An open access version is available from UCL Discovery
DOI: 10.1056/NEJMoa030505
Publisher version: http://dx.doi.org/10.1056/NEJMoa030505
Language: English
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Brain Repair and Rehabilitation
URI: https://discovery-pp.ucl.ac.uk/id/eprint/7380
Downloads since deposit
175,788Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item